Cargando…

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease

AIMS: Pridopidine is an oral drug in clinical development for treatment of patients with Huntington's disease. This study examined the interactions of pridopidine with in vitro cytochrome P450 activity and characterized the effects of pridopidine on CYP2D6 activity in healthy volunteers using m...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabinovich‐Guilatt, Laura, Steiner, Lilach, Hallak, Hussein, Pastino, Gina, Muglia, Pierandrea, Spiegelstein, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595947/
https://www.ncbi.nlm.nih.gov/pubmed/28449367
http://dx.doi.org/10.1111/bcp.13317
_version_ 1783263450566230016
author Rabinovich‐Guilatt, Laura
Steiner, Lilach
Hallak, Hussein
Pastino, Gina
Muglia, Pierandrea
Spiegelstein, Ofer
author_facet Rabinovich‐Guilatt, Laura
Steiner, Lilach
Hallak, Hussein
Pastino, Gina
Muglia, Pierandrea
Spiegelstein, Ofer
author_sort Rabinovich‐Guilatt, Laura
collection PubMed
description AIMS: Pridopidine is an oral drug in clinical development for treatment of patients with Huntington's disease. This study examined the interactions of pridopidine with in vitro cytochrome P450 activity and characterized the effects of pridopidine on CYP2D6 activity in healthy volunteers using metoprolol as a probe substrate. The effect of food on pridopidine exposure was assessed. METHODS: The ability of pridopidine to inhibit and/or induce in vitro activity of drug metabolizing enzymes was examined in human liver microsomes and fresh hepatocytes. CYP2D6 inhibition potency and reversibility was assessed using dextromethorphan. For the clinical assessment, 22 healthy subjects were given metoprolol 100 mg alone and concomitantly with steady‐state pridopidine 45 mg twice daily. Food effect on a single 90 mg dose of pridopidine was evaluated in a crossover manner. Safety assessments and pharmacokinetic sampling occurred throughout the study. RESULTS: Pridopidine was found to be a metabolism dependent inhibitor of CYP2D6, the main enzyme catalysing its own metabolism. Flavin‐containing monooxygenase heat inactivation of liver microsomes did not affect pridopidine metabolism‐dependent inhibition of CYP2D6 and its inhibition of CYP2D6 was not reversible with addition of FeCN(3). Exposure to metoprolol was markedly increased when coadministered with pridopidine; the ratio of the geometric means (90% confidence interval) for maximum observed plasma concentration, and area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration and extrapolated to infinity were 3.5 (2.9, 4.22), 6.64 (5.27, 8.38) and 6.55 (5.18, 8.28), respectively. Systemic exposure to pridopidine was unaffected by food conditions. CONCLUSIONS: As pridopidine is a metabolism‐dependent inhibitor of CYP2D6, systemic levels of drugs metabolized by CYP2D6 may increase with chronic coadministration of pridopidine. Pridopidine can be administered without regard to food.
format Online
Article
Text
id pubmed-5595947
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55959472017-09-15 Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease Rabinovich‐Guilatt, Laura Steiner, Lilach Hallak, Hussein Pastino, Gina Muglia, Pierandrea Spiegelstein, Ofer Br J Clin Pharmacol Drug Interactions AIMS: Pridopidine is an oral drug in clinical development for treatment of patients with Huntington's disease. This study examined the interactions of pridopidine with in vitro cytochrome P450 activity and characterized the effects of pridopidine on CYP2D6 activity in healthy volunteers using metoprolol as a probe substrate. The effect of food on pridopidine exposure was assessed. METHODS: The ability of pridopidine to inhibit and/or induce in vitro activity of drug metabolizing enzymes was examined in human liver microsomes and fresh hepatocytes. CYP2D6 inhibition potency and reversibility was assessed using dextromethorphan. For the clinical assessment, 22 healthy subjects were given metoprolol 100 mg alone and concomitantly with steady‐state pridopidine 45 mg twice daily. Food effect on a single 90 mg dose of pridopidine was evaluated in a crossover manner. Safety assessments and pharmacokinetic sampling occurred throughout the study. RESULTS: Pridopidine was found to be a metabolism dependent inhibitor of CYP2D6, the main enzyme catalysing its own metabolism. Flavin‐containing monooxygenase heat inactivation of liver microsomes did not affect pridopidine metabolism‐dependent inhibition of CYP2D6 and its inhibition of CYP2D6 was not reversible with addition of FeCN(3). Exposure to metoprolol was markedly increased when coadministered with pridopidine; the ratio of the geometric means (90% confidence interval) for maximum observed plasma concentration, and area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration and extrapolated to infinity were 3.5 (2.9, 4.22), 6.64 (5.27, 8.38) and 6.55 (5.18, 8.28), respectively. Systemic exposure to pridopidine was unaffected by food conditions. CONCLUSIONS: As pridopidine is a metabolism‐dependent inhibitor of CYP2D6, systemic levels of drugs metabolized by CYP2D6 may increase with chronic coadministration of pridopidine. Pridopidine can be administered without regard to food. John Wiley and Sons Inc. 2017-06-21 2017-10 /pmc/articles/PMC5595947/ /pubmed/28449367 http://dx.doi.org/10.1111/bcp.13317 Text en © 2017 Teva Pharmaceutical Industries Ltd. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Drug Interactions
Rabinovich‐Guilatt, Laura
Steiner, Lilach
Hallak, Hussein
Pastino, Gina
Muglia, Pierandrea
Spiegelstein, Ofer
Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
title Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
title_full Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
title_fullStr Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
title_full_unstemmed Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
title_short Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
title_sort metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of huntington's disease
topic Drug Interactions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595947/
https://www.ncbi.nlm.nih.gov/pubmed/28449367
http://dx.doi.org/10.1111/bcp.13317
work_keys_str_mv AT rabinovichguilattlaura metoprololpridopidinedrugdruginteractionandfoodeffectassessmentsofpridopidineanewdrugfortreatmentofhuntingtonsdisease
AT steinerlilach metoprololpridopidinedrugdruginteractionandfoodeffectassessmentsofpridopidineanewdrugfortreatmentofhuntingtonsdisease
AT hallakhussein metoprololpridopidinedrugdruginteractionandfoodeffectassessmentsofpridopidineanewdrugfortreatmentofhuntingtonsdisease
AT pastinogina metoprololpridopidinedrugdruginteractionandfoodeffectassessmentsofpridopidineanewdrugfortreatmentofhuntingtonsdisease
AT mugliapierandrea metoprololpridopidinedrugdruginteractionandfoodeffectassessmentsofpridopidineanewdrugfortreatmentofhuntingtonsdisease
AT spiegelsteinofer metoprololpridopidinedrugdruginteractionandfoodeffectassessmentsofpridopidineanewdrugfortreatmentofhuntingtonsdisease